Detailed Information on Publication Record
2009
Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: Frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression
DOUBEK, Michael, Ivo PALÁSEK, Zdeněk POSPÍŠIL, Marek BORSKÝ, Martin KLABUSAY et. al.Basic information
Original name
Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: Frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression
Name in Czech
Detekce a léčba molekulárního relapsu při akutní myeloidní leukemii s genovými translokacemi RUNX1 (AML1), CBFB nebo MLL: Častý kvantitativní monitoring molekulárních markerů v různých kompartmentech a korelace s expresí genu WT1
Authors
DOUBEK, Michael (203 Czech Republic, guarantor, belonging to the institution), Ivo PALÁSEK (203 Czech Republic, belonging to the institution), Zdeněk POSPÍŠIL (203 Czech Republic, belonging to the institution), Marek BORSKÝ (203 Czech Republic, belonging to the institution), Martin KLABUSAY (203 Czech Republic, belonging to the institution), Yvona BRYCHTOVÁ (203 Czech Republic, belonging to the institution), Tomáš JURČEK (203 Czech Republic, belonging to the institution), Ivana JEŽÍŠKOVÁ (203 Czech Republic), Marta KREJČÍ (203 Czech Republic, belonging to the institution), Dana DVOŘÁKOVÁ (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution)
Edition
Experimental Hematology, Elsevier, 2009, 0301-472X
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 3.106
RIV identification code
RIV/00216224:14110/09:00067132
Organization unit
Faculty of Medicine
UT WoS
000266458200002
Keywords (in Czech)
Minimální reziduální choroba; reakce polymerázového řetězce; akutní promyelocytická leukemie; akutní lymfoblastická leukemie; RT-PCR; Gemtuzumab ozogamycin; fúzní transkript; prognostická hodnota; kostní dřeň
Keywords in English
MINIMAL RESIDUAL DISEASE; POLYMERASE-CHAIN-REACTION; ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; RT-PCR; GEMTUZUMAB OZOGAMICIN; FUSION TRANSCRIPTS; PROGNOSTIC VALUE; CANCER PROGRAM; BONE-MARROW
Tags
Tags
International impact, Reviewed
Změněno: 29/4/2014 09:29, Ing. Mgr. Věra Pospíšilíková
V originále
Objective. Our objective was to determine the value of frequent minimal residual disease (MRD) monitoring in acute myeloid leukemia (AML) as a robust marker of impending relapse, and whether treatment benefits patients during the MRD-positive phase of their disease. Materials and Methods. Frequent MRD monitoring was performed in all AMI, treatment phases using real-time quantitative polymerase chain reaction for fusion transcripts (CBFB/MYH11; RUNX1/RUNX1T1 fusion transcripts of MLL gene) and for the Wilms' tumor (WT1) gene. A total of 2,664 samples, taken from 79 AML patients and 6 healthy volunteers, were examined. Presence of fusion gene was detected in 25 of 79 examined patients. Results. Vast correlation was discovered for fusion transcripts as well as for the 1471 gene between levels in bone marrow (BM), peripheral blood, CD34(+) BM cells, and CD34(-) BM cells. WT1 expression, however, was usually positive for cases showing fusion transcripts negativity and in health), volunteers. Moreover, no universal value of the WT1 expression could unequivocally discriminate between remission and relapse. Therefore, detection of molecular relapses relied on fusion transcripts only and was characterized by strong expression in CD34(+) cells. Considering relapsed patients, duration from molecular to hematological relapse was 8 to 79 days (median: 25.5 days). Twelve patients were treated (chemotherapy, gemtuzumab ozogamicin, or immunomodulation after allogeneic transplantation) for 21 molecular relapses and 14 responses to treatment were observed. Conclusions. Frequent quantitative monitoring of fusion transcripts is useful for reliably predicting hematological relapse in AML patients. Treatment for molecular relapse of AML can be successful.
In Czech
Častý kvantitativní monitoring fúzních transkriptů přispívá ke spolehlivé predikci hematologického relapsu u pacientů s AML. Léčba molekulárního relapsu může být úspěšná.
Links
| MSM0021622430, plan (intention) |
|